

Brian Whalen
on behalf of Sanford ME
LD 1847

Balancing public-health goals against economic reality, the evidence shows LD 104 is premature. Testing every batch is admirable in theory, but with few labs and no fee relief, the bill shifts nearly all risk onto small caregivers and the low-income patients who rely on affordable medicine. A phased-in program would deliver cleaner product data without wiping out an industry that supports thousands of Maine jobs.